MeSH term
Frequency | Condition_Probility | Animals | 24 | 0.0 |
Comparative Study | 12 | 0.0 |
English Abstract | 10 | 0.0 |
Interleukin-10/*blood | 5 | 15.0 |
Male | 51 | 0.0 |
Mice | 9 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Th1 Cells/immunology | 4 | 2.0 |
Th2 Cells/immunology | 3 | 1.0 |
Adult | 40 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Female | 53 | 0.0 |
Flow Cytometry | 10 | 0.0 |
Humans | 111 | 0.0 |
Interleukin-10/*secretion | 2 | 18.0 |
Research Support, Non-U.S. Gov't | 64 | 0.0 |
Antigens, CD/blood | 2 | 0.0 |
CD4-CD8 Ratio | 2 | 0.0 |
Middle Aged | 36 | 0.0 |
Time Factors | 5 | 0.0 |
Age of Onset | 3 | 0.0 |
Aged | 22 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Gene Frequency | 5 | 0.0 |
Genetic Predisposition to Disease | 6 | 0.0 |
Interleukin-10/genetics | 6 | 13.0 |
Polymorphism, Genetic | 4 | 0.0 |
Tumor Necrosis Factor-alpha/*genetics | 3 | 0.0 |
CD4 Lymphocyte Count | 2 | 0.0 |
Interferon Type II/metabolism | 3 | 1.0 |
Interleukin-10/metabolism | 4 | 6.0 |
Interleukin-2/metabolism | 3 | 2.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 4 | 0.0 |
Adolescent | 11 | 0.0 |
Base Sequence | 4 | 0.0 |
Child | 10 | 0.0 |
DNA Primers | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
Risk Factors | 3 | 0.0 |
Antigens, CD4/analysis | 2 | 0.0 |
Antigens, CD8/analysis | 2 | 0.0 |
Cytokines/analysis | 2 | 2.0 |
Leukocytes, Mononuclear/drug effects/immunology | 2 | 4.0 |
Hela Cells | 2 | 0.0 |
Polymorphism, Single Nucleotide | 3 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Biopsy | 3 | 0.0 |
Gene Expression | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 11 | 0.0 |
Cytokines/*biosynthesis | 7 | 1.0 |
Interferon Type II/secretion | 3 | 2.0 |
Interleukin-10/secretion | 3 | 9.0 |
Interleukin-6/secretion | 2 | 3.0 |
Pilot Projects | 2 | 0.0 |
Reference Values | 3 | 0.0 |
Tumor Necrosis Factor-alpha/secretion | 3 | 2.0 |
Enzyme-Linked Immunosorbent Assay | 10 | 0.0 |
Prospective Studies | 5 | 0.0 |
Child, Preschool | 7 | 0.0 |
Odds Ratio | 4 | 0.0 |
Interferon Type II/blood/metabolism | 2 | 40.0 |
Interleukin-10/blood/metabolism | 2 | 66.0 |
Interleukin-12/blood/metabolism | 2 | 40.0 |
Antibodies, Monoclonal/*therapeutic use | 2 | 0.0 |
Case-Control Studies | 8 | 0.0 |
Cytokines/*metabolism | 2 | 0.0 |
Interleukin-4/metabolism | 4 | 4.0 |
Statistics, Nonparametric | 5 | 0.0 |
Tumor Necrosis Factor-alpha/*immunology | 2 | 1.0 |
Biological Markers | 2 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Interferon Type II/*biosynthesis | 2 | 1.0 |
Interleukin-10/biosynthesis | 5 | 4.0 |
Longitudinal Studies | 3 | 0.0 |
Cytokines/*analysis | 3 | 3.0 |
Immunophenotyping | 3 | 0.0 |
Interferon Type II/analysis | 4 | 4.0 |
Interleukin-10/analysis | 4 | 11.0 |
Interleukin-2/analysis | 2 | 4.0 |
Interleukin-4/analysis | 4 | 10.0 |
Th1 Cells/*immunology | 4 | 2.0 |
Analysis of Variance | 3 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Leukocytes, Mononuclear/*drug effects/immunology/metabolism | 2 | 25.0 |
Cytokines/immunology | 2 | 1.0 |
Pregnancy | 2 | 0.0 |
Chronic Disease | 6 | 0.0 |
Cell Division | 4 | 0.0 |
Interleukin-10/*biosynthesis | 4 | 6.0 |
Interleukin-4/*biosynthesis | 2 | 3.0 |
Acute Disease | 7 | 0.0 |
*Alleles | 2 | 0.0 |
Disease Progression | 5 | 0.0 |
Microsatellite Repeats | 3 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Administration, Oral | 2 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Infant | 4 | 0.0 |
Cytokines/*blood | 5 | 1.0 |
Alleles | 4 | 0.0 |
Genotype | 11 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Phenotype | 2 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
T-Lymphocytes/*immunology | 4 | 0.0 |
Interleukin-10/*genetics | 11 | 24.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Bone Marrow Cells/cytology | 2 | 2.0 |
Cell Death | 2 | 0.0 |
Cell Division/drug effects | 5 | 0.0 |
Cell Membrane | 2 | 3.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
Dinoprostone/*pharmacology | 2 | 3.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Drug Resistance | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Glioma/*immunology | 2 | 13.0 |
Immunosuppressive Agents/pharmacology | 2 | 1.0 |
Interleukin-10/*pharmacology | 2 | 2.0 |
Macrophage Colony-Stimulating Factor/biosynthesis/*physiology | 2 | 100.0 |
Macrophages/drug effects/*immunology/metabolism | 2 | 25.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Phosphodiesterase Inhibitors/pharmacology | 2 | 1.0 |
Rats | 3 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Theophylline/pharmacology | 2 | 5.0 |
Tumor Cells, Cultured | 6 | 0.0 |
Cytokines/*secretion | 3 | 5.0 |
European Continental Ancestry Group | 2 | 0.0 |
Cell Line | 4 | 0.0 |
Interferon Type II/biosynthesis | 4 | 0.0 |
Genetic Markers | 2 | 0.0 |
Haplotypes | 6 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Cytokines/biosynthesis | 4 | 0.0 |
Interleukin-10/blood | 2 | 2.0 |
Treatment Outcome | 2 | 0.0 |
Interferon Type II/immunology | 3 | 3.0 |
Lymphocyte Activation/immunology | 3 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Adenine | 2 | 3.0 |
Gene Frequency/genetics | 2 | 0.0 |
Guanine | 2 | 2.0 |
Periodontitis/genetics/*immunology | 2 | 28.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Sex Factors | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Receptors, IgG/*immunology | 3 | 9.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*blood | 2 | 25.0 |
Interferon Type II/*blood | 2 | 6.0 |
Interleukin-8/*blood | 2 | 5.0 |
Receptors, IgE/*blood | 2 | 28.0 |
Cytokines/genetics/*metabolism | 2 | 5.0 |
Leukocyte Count | 2 | 0.0 |
Up-Regulation | 3 | 0.0 |
T-Lymphocyte Subsets/immunology | 2 | 0.0 |
Molecular Sequence Data | 3 | 0.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Antigens, CD3/immunology | 2 | 0.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Cytokines/*immunology | 3 | 3.0 |
Tumor Necrosis Factor-alpha/immunology | 2 | 1.0 |
Cytokines/*genetics | 2 | 1.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Immunity, Cellular | 2 | 0.0 |
Phytohemagglutinins/pharmacology | 3 | 0.0 |
Signal Transduction | 2 | 0.0 |
Tumor Necrosis Factor-alpha/genetics | 2 | 0.0 |
Th2 Cells/*immunology | 2 | 1.0 |
Swine | 2 | 0.0 |
Autoantigens/immunology | 2 | 1.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
Erythrocytes/*immunology | 2 | 1.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Interleukin-6/*biosynthesis | 2 | 1.0 |
Disease Models, Animal | 2 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Inflammation/immunology | 2 | 1.0 |
Immunoglobulin E/blood | 2 | 1.0 |
Survival Analysis | 2 | 0.0 |
Cohort Studies | 3 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Principal Component Analysis | 2 | 9.0 |
In Vitro | 2 | 0.0 |
Interleukins/blood | 2 | 5.0 |
Infant, Newborn | 2 | 0.0 |
Interleukin-6/biosynthesis | 2 | 0.0 |
